Recent clinical studies surrounding Retatrutide , specifically the 120mg formulation referred to as ZPHC, indicate a significant effect on weight reduction and linked chronic factors. Scientists posit that this dual agonist , targeting both GLP-1 and GIP receptors , could provide a noteworthy adv